Latest Breaking News On - Participants with moderately - Page 1 : comparemela.com

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie s commitment to produce a portfolio of products that aim to improve the lives of patients.

Guselkumab for the Treatment of Crohn Disease, with Remo Panaccione, MD

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.

Guselkumab Demonstrates Long-Term Benefit for Crohn Disease

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023